Switch theme
Sign up to access all valuation multiples
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
1969
4.4K+
LTM Revenue $1.6B
LTM EBITDA $318M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Integra Lifesciences has a last 12-month revenue (LTM) of $1.6B and a last 12-month EBITDA of $318M.
In the most recent fiscal year, Integra Lifesciences achieved revenue of $1.6B and an EBITDA of $193M.
Integra Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Integra Lifesciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $1.0B | XXX | $882M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $318M | XXX | $193M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $273M | XXX | $28.4M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $186M | XXX | -$6.9M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.6B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Integra Lifesciences's stock price is $13.
Integra Lifesciences has current market cap of $983M, and EV of $2.7B.
See Integra Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $983M | XXX | XXX | XXX | XXX | $2.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Integra Lifesciences has market cap of $983M and EV of $2.7B.
Integra Lifesciences's trades at 1.7x EV/Revenue multiple, and 14.1x EV/EBITDA.
Equity research analysts estimate Integra Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Integra Lifesciences has a P/E ratio of 5.3x.
See valuation multiples for Integra Lifesciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $983M | XXX | $983M | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 14.1x | XXX | XXX | XXX |
| EV/EBIT | 10.0x | XXX | 96.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 5.3x | XXX | -141.6x | XXX | XXX | XXX |
| EV/FCF | 36.2x | XXX | 181.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIntegra Lifesciences's last 12 month revenue growth is 4%
Integra Lifesciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Integra Lifesciences's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Integra Lifesciences's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Integra Lifesciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Integra Lifesciences acquired XXX companies to date.
Last acquisition by Integra Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Integra Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Integra Lifesciences founded? | Integra Lifesciences was founded in 1969. |
| Where is Integra Lifesciences headquartered? | Integra Lifesciences is headquartered in United States of America. |
| How many employees does Integra Lifesciences have? | As of today, Integra Lifesciences has 4.4K+ employees. |
| Who is the CEO of Integra Lifesciences? | Integra Lifesciences's CEO is Ms. Mojdeh Poul. |
| Is Integra Lifesciences publicy listed? | Yes, Integra Lifesciences is a public company listed on NAS. |
| What is the stock symbol of Integra Lifesciences? | Integra Lifesciences trades under IART ticker. |
| When did Integra Lifesciences go public? | Integra Lifesciences went public in 1995. |
| Who are competitors of Integra Lifesciences? | Similar companies to Integra Lifesciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Integra Lifesciences? | Integra Lifesciences's current market cap is $983M |
| What is the current revenue of Integra Lifesciences? | Integra Lifesciences's last 12 months revenue is $1.6B. |
| What is the current revenue growth of Integra Lifesciences? | Integra Lifesciences revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Integra Lifesciences? | Current revenue multiple of Integra Lifesciences is 1.7x. |
| Is Integra Lifesciences profitable? | Yes, Integra Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Integra Lifesciences? | Integra Lifesciences's last 12 months EBITDA is $318M. |
| What is Integra Lifesciences's EBITDA margin? | Integra Lifesciences's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Integra Lifesciences? | Current EBITDA multiple of Integra Lifesciences is 8.6x. |
| What is the current FCF of Integra Lifesciences? | Integra Lifesciences's last 12 months FCF is $75.5M. |
| What is Integra Lifesciences's FCF margin? | Integra Lifesciences's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Integra Lifesciences? | Current FCF multiple of Integra Lifesciences is 36.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
